Novartis announced FDA approval of Arcapta Neohaler (indacaterol inhalation powder) for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Arcapta Neohaler demonstrated improvements in lung function and also is approved with data demonstrating improvement in health-related quality of life.

Arcapta Neohaler is a long acting beta2-agonist for maintenance treatment of airflow obstruction in patients with COPD.

For more information call (888) NOW-NOVA or visit www.pharma.us.novartis.com/info/products.